MAIA Biotechnology, Inc. (MAIA)
Business numbers score is on the low side; price trend score is near the bottom of its range, smart-money score is near the top of its range.
MAIA scores higher than 29% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, MAIA Biotechnology, Inc. (MAIA) scores 29 out of 100 on the Market Census six-factor composite, which puts it at the Below average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.62× 30-day average
- 52-week range
- 0.87 – 3.19
- Market cap
- $79.69M
- Earnings date
- 5 Nov 2026
- Volume
- 375,248
- Avg. volume (30d)
- 609,999
- Open
- 1.16
- Previous close
- 1.15
- Day's range (regular session)
- 1.16 – 1.24
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for MAIA
- 7 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for MAIA. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about MAIA right now
MAIA Biotechnology, Inc. (MAIA) currently scores 29/100 on the Market Census six-factor composite, at the Below average score level. MAIA is +6.09% on the day and +2.52% over five sessions as of the most recent tick. Below average sits a bit below the middle. More of MAIA's data reads poorly than well. The level is a "look before you act" flag. It is not advice. MAIA's strongest factor is insider trades at 90/100 — a very strong read on insider buying and selling. Insider filings currently lean toward buying on this name — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See MAIA in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent MAIA news
Latest headlines that name MAIA Biotechnology, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerYahoo
- MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung CancerBenzinga
- MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding AgreementBenzinga
- MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and PortugalYahoo
- MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung CancerBenzinga
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to MAIA’s 29, all within 1 point.
Sorted by closeness to MAIA’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.